Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection

OBJECTIVES: In some patients the immune response triggered by SARS-CoV-2 is unbalanced, presenting an acute respiratory distress syndrome which in many cases requires intensive care unit (ICU) admission. The limitation of ICU beds has been one of the major burdens in the management around the world;...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Rev Esp Quimioter
Autors principals: Moreno-García, Estela, Rico, Verónica, Albiach, Laia, Agüero, Daiana, Ambrosioni, Juan, Bodro, Marta, Cardozo, Celia, Chumbita, Mariana, De la Mora, Lorena, García-Pouton, Nicole, Garcia-Vidal, Carolina, González-Cordón, Ana, Hernández-Meneses, Marta, Inciarte, Alexy, Laguno, Montse, Leal, Lorna, Linares, Laura, Macaya, Irene, Meira, Fernanda, Mensa, Josep, Moreno, Antonio, Morata, Laura, Puerta-Alcalde, Pedro, Rojas, Jhon, Solá, Montse, Torres, Berta, Torres, Manuel, Tomé, Adrià, Tuset, Montse, Castro, Pedro, Fernández, Sara, Nicolás, Josep Maria, Almuedo-Riera, Alex, Muñoz, Jose, Fernandez-Pittol, Mariana, Marcos, Maria Angeles, Soy, Dolors, Martínez, José Antonio, García, Felipe, Soriano, Alex
Format: Artigo
Idioma:Inglês
Publicat: Sociedad Española de Quimioterapia 2021
Matèries:
Original
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8179941/
https://ncbi.nlm.nih.gov/pubmed/33829722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.37201/req/037.2021
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars